- Conditions
- Hereditary Angioedema
- Interventions
- C1 inhibitor (human) [C1 INH]
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Wheaton, Maryland + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 1,851
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Photo therapy
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Cancer
- Interventions
- infection prophylaxis and management
- Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2002
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic-granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Schwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia
- Interventions
- Alefacept
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Gyrate Atrophy
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1978 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Skin Lesion, Skin Abnormalities, Sebaceous Hyperplasia
- Interventions
- Nano-Pulse Stimulation Device
- Device
- Lead sponsor
- Pulse Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 5
- States / cities
- Sacramento, California • San Mateo, California • Chestnut Hill, Massachusetts + 2 more
- Conditions
- Mucopolysaccharidosis VI
- Interventions
- N-acetylgalactosamine 4-sulfatase
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Novato, California
- Conditions
- Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset
- Interventions
- IL-1 Trap
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atopic Dermatitis
- Interventions
- Pimecrolimus, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 200 participants
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Novartis Pharmaceuticals, New Jersey
- Conditions
- Skin Laxity, Wrinkle, Skin Condition
- Interventions
- Profound Matrix
- Device
- Lead sponsor
- Candela Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Marlborough, Massachusetts • Fayetteville, North Carolina + 1 more
- Conditions
- Erythropoietic Protoporphyria (EPP)
- Interventions
- MT-7117 low dose, MT-7117 high dose, Placebo
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
- Conditions
- Atopic Dermatitis
- Interventions
- Rocatinlimab, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 726 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 69
- States / cities
- Litchfield Park, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 58 more
- Conditions
- Wrinkle, Fine Lines, Crepey Skin, Acne Scars, Active Acne, Enlarged Pores, Stretch Mark, Loose Skin
- Interventions
- RadioFrequency Microneedling Device
- Device
- Lead sponsor
- Cynosure, Inc.
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Westford, Massachusetts
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- recombinant interleukin-12
- Biological
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Erythropoietic Protoporphyria
- Interventions
- Afamelanotide, Placebo
- Drug
- Lead sponsor
- Clinuvel Pharmaceuticals Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • Detroit, Michigan + 4 more
- Conditions
- Atopic Dermatitis
- Interventions
- Roseomonas mucosa
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 99 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Deucrictibant
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Moisturizer with each subject's own antimicrobial bacteria
- Biological
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 35 more
- Conditions
- Craniofacial Microsomia, Hemifacial Microsomia, Oculo-Auriculo-Vertebral-Syndrome, Goldenhar Syndrome, Microtia
- Interventions
- Not listed
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 12 Months to 24 Months
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Chicago, Illinois • Chapel Hill, North Carolina + 2 more
- Conditions
- Netherton Syndrome
- Interventions
- QRX003, 4% Lotion
- Drug
- Lead sponsor
- Quoin Pharmaceuticals
- Industry
- Eligibility
- 14 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 1 more
- Conditions
- Atopic Dermatitis
- Interventions
- PF-07275315, PF-07264660, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 42 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Pimecrolimus plus topical corticosteroid (TCS), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 13
- States / cities
- Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania